DeepCovalent Therapeutic Pipeline

In Silico–Validated Novel Compounds Generated by OS3D™

We intend to advance early pre-clinical development of these compounds, through at least (i) in vitro pharmacology and receptor characterization, and (ii) pharmacokinetics and absorption studies in animals (including oral bioavailability), in order to drive compound valuation for potential licensing to or acquisition by pharma partners.

We have identified an additional eleven backup compounds for potential pre-clinical development in our pipeline.

Our GLP-1R small-molecule candidates were validated using a comprehensive in-silico framework, including structure-based docking and binding analysis, receptor conformational assessment, MD simulations with stability analysis, physics-based MM/GBSA free-energy calculations, off-target selectivity modeling, ADMET profiling, and synthetic accessibility scoring.

Compared to reference compounds such as orforglipron (Eli Lilly), danuglipron (Pfizer), and lotiglipron (Pfizer), our compounds exhibit:

• Significantly fewer predicted ADMET risks

• Improved predicted off-target selectivity

• Multiple structurally diverse candidates with distinct small-molecule chemotypes

• Stable predicted binding complexes by MD trajectory analysis and MM/GBSA free-energy calculations

• Strong synthetic accessibility, supporting rapid synthesis and progression